Presentation at Drug Delivery Partnerships 2016 will offer best practices for effective patient onboarding with wearable self-injection systems
EXTON, Pa., Jan. 20, 2016 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug containment and delivery, today announced that the company is collaborating with Noble®, a leader in patient-centric onboarding and training, to provide multisensory-based educational and training programs for self-injection systems. West will now have the ability to offer its pharmaceutical and biotech customers validated training solutions for theSmartDose® Electronic Wearable Injector and other innovative self-administration systems from West. This collaboration with Noble complements West's established relationships with other innovative design firms such as Insight Product Development and HealthPrize Technologies to enhance its patient-centric approach to drug delivery systems.
"Advancements in biologic products coupled with the shift to patient self-care in the home setting have driven the need for enhanced self-injection systems," said Chris Evans, Vice President of Research & Innovation at West. "We work by the side of our customers and partners to optimize the experience of patients who self-inject in a way that increases affinity, overcomes initial training and onboarding challenges, and fosters adherence to a treatment regimen."
According to a recent study by Noble and analyzed by Auburn University, more than 60 percent of patients self-reported that they did not thoroughly read the required steps outlined in a self-injection system's Instructions for Use document prior to beginning drug treatment, potentially leading to administration errors and impacting compliance with prescribed therapies.
"New patients with self-injectors often make errors in administration. It is not surprising that when patients don't have the necessary education and resources to use their self-injection system as intended, then expected patient outcomes are not achieved," saidCraig Baker, Executive Vice President at Noble. "Research from both West and Noble revealed that patient-friendly delivery systems and comprehensive education around self-injection are needed to improve the patient experience."
West and Noble are teaming up to offer multisensory education programs and technologies for wearable self-injectors. West applies human factors testing and analysis to the design of drug delivery systems to improve the patient journey. Noble incorporates similar human factors principles into the development of patient training technologies and education materials, including instructions for use, onboarding, smart training devices and packaging. By combining these offerings, West and Noble aim to help improve the patient experience, reduce errors and anxiety, and increase adherence to prescribed injectable therapies.
Drug Delivery Partnerships 2016 Conference Presentation
"Effective Patient Training and Onboarding for Wearable Injection Devices"
January 20, 2016, 11:45 a.m. (EST)
Chris Evans from West and Joe Reynolds from Noble will co-present this session on the process of holistic drug delivery and education as part of the Top Drug Delivery Technologies to Watch track. They will discuss how multisensory-based device training programs can help ensure proper device use. Additionally, they will share best practices for developing effective training packages for the next generation of self-administration combination products.
To learn more about West's portfolio of solutions for injectable drug administration, please visit www.westpharma.com.
West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West's 2014 sales of $1.42 billionreflect the daily use of approximately 110 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.
Noble®, the leader in onboarding and device training, is a patient-centered product development and manufacturing company. Noble works closely with the world's leading pharmaceutical and biotechnology companies to develop educational and training solutions that improve the patient journey. Cross-disciplinary designers and engineers provide fully customized solutions from the first concept sketch through production in both regulated and non-regulated environments. Noble is headquartered in Orlando, Florida.
West and the diamond logo are registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
SmartDose® is a registered trademark of Medimop Medical Projects Ltd., a subsidiary of West Pharmaceutical Services, Inc. West seeks partners for its SmartDose electronic wearable injector technology platform. This platform is intended to be used as an integrated system with drug filling and final assembly completed by the pharmaceutical/biotechnology company.
Global Communications, West Pharmaceutical Services
SOURCE West Pharmaceutical Services, Inc.